WO2009001857A1 - 低酸素または虚血に伴う眼疾患用組成物 - Google Patents

低酸素または虚血に伴う眼疾患用組成物 Download PDF

Info

Publication number
WO2009001857A1
WO2009001857A1 PCT/JP2008/061545 JP2008061545W WO2009001857A1 WO 2009001857 A1 WO2009001857 A1 WO 2009001857A1 JP 2008061545 W JP2008061545 W JP 2008061545W WO 2009001857 A1 WO2009001857 A1 WO 2009001857A1
Authority
WO
WIPO (PCT)
Prior art keywords
hypoxia
ischemia
disease associated
composition
ophthalmic disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/061545
Other languages
English (en)
French (fr)
Inventor
Yukihiko Mashima
Naomi Kurono
Nami Yoshikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
R Tech Ueno Ltd
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Priority to JP2009520615A priority Critical patent/JPWO2009001857A1/ja
Priority to CA002691520A priority patent/CA2691520A1/en
Priority to CN2008801043488A priority patent/CN101784285B/zh
Priority to EP08790612A priority patent/EP2172221A4/en
Priority to US12/665,914 priority patent/US20100190834A1/en
Publication of WO2009001857A1 publication Critical patent/WO2009001857A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　本発明によれば、ＶＡＰ－１阻害剤を有効成分として含む、低酸素あるいは虚血に伴う眼疾患に有効な組成物を提供することができる。また本発明によれば、低酸素または虚血に伴う病的な血管新生を抑制する血管新生抑制剤を提供することができる。
PCT/JP2008/061545 2007-06-25 2008-06-25 低酸素または虚血に伴う眼疾患用組成物 Ceased WO2009001857A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2009520615A JPWO2009001857A1 (ja) 2007-06-25 2008-06-25 低酸素または虚血に伴う眼疾患用組成物
CA002691520A CA2691520A1 (en) 2007-06-25 2008-06-25 Composition for ophthalmic disease associated with hypoxia or ischemia
CN2008801043488A CN101784285B (zh) 2007-06-25 2008-06-25 用于与低氧或局部缺血有关的眼科疾病的组合物
EP08790612A EP2172221A4 (en) 2007-06-25 2008-06-25 COMPOSITION FOR OPHTHALMIC DISEASE ASSOCIATED WITH HYPOXIA OR ISCHEMIA
US12/665,914 US20100190834A1 (en) 2007-06-25 2008-06-25 Composition for ophtalmic disease associated with hypoxia or ischemia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007166989 2007-06-25
JP2007-166989 2007-06-25

Publications (1)

Publication Number Publication Date
WO2009001857A1 true WO2009001857A1 (ja) 2008-12-31

Family

ID=40185670

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061545 Ceased WO2009001857A1 (ja) 2007-06-25 2008-06-25 低酸素または虚血に伴う眼疾患用組成物

Country Status (8)

Country Link
US (1) US20100190834A1 (ja)
EP (2) EP2599498A1 (ja)
JP (2) JPWO2009001857A1 (ja)
KR (1) KR20100034024A (ja)
CN (2) CN102920698A (ja)
CA (1) CA2691520A1 (ja)
TW (1) TW200913999A (ja)
WO (1) WO2009001857A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009145360A1 (en) * 2008-05-30 2009-12-03 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as vap-1 inhibitor
EP2213303A4 (en) * 2007-10-19 2011-12-28 R Tech Ueno Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
US8507690B2 (en) 2008-01-31 2013-08-13 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067521A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
WO2004087138A1 (en) * 2003-03-31 2004-10-14 Sucampo Ag Method for treating vascular hyperpermeable disease
WO2006011631A2 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
WO2008066145A1 (en) * 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2579889A1 (en) 2004-09-09 2006-03-16 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067521A1 (en) * 2003-01-27 2004-08-12 Astellas Pharma Inc. Thiazole derivatives and their use as vap-1 inhibitors
WO2004087138A1 (en) * 2003-03-31 2004-10-14 Sucampo Ag Method for treating vascular hyperpermeable disease
WO2006011631A2 (en) * 2004-07-27 2006-02-02 Astellas Pharma Inc. Thiazole derivatives having vap-1 inhibitory activity
WO2008066145A1 (en) * 2006-11-30 2008-06-05 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as vap-1 inhibitor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] DURA E.: "The potential role of the semicarbazide-sensitive amine oxidase activity in the development of diabetic retinopathy", XP008117785, Database accession no. (EMB-2006357862) *
E. DURA, LEGE ARTIS MEDICINE, vol. 16, no. 7, 2006, pages 637 - 642
GARPENSTRAND H. ET AL.: "Serum semicarbazide-sensitive amin oxidase (SSAO) activity correlates with VEGF in non-small-cell lung cancer patients", MEDICAL ONCOLOGY, vol. 21, no. 3, 2004, pages 241 - 250, XP009121090 *
GOKTURK ET AL., BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, vol. 1647, no. 1-2, 2003, pages 88 - 91
LEGE ARTIS MEDICINE, vol. 16, no. 7, 2006, pages 637 - 642 *
See also references of EP2172221A4

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2213303A4 (en) * 2007-10-19 2011-12-28 R Tech Ueno Ltd PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
US8507690B2 (en) 2008-01-31 2013-08-13 R-Tech Ueno, Ltd. Thiazole derivative and use thereof as VAP-1 inhibitor
WO2009145360A1 (en) * 2008-05-30 2009-12-03 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as vap-1 inhibitor
JP2011523649A (ja) * 2008-05-30 2011-08-18 株式会社アールテック・ウエノ ベンゼンまたはチオフェン誘導体およびｖａｐ−１阻害剤としてのその使用
US8999989B2 (en) 2008-05-30 2015-04-07 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
US9603833B2 (en) 2008-05-30 2017-03-28 R-Tech Ueno, Ltd. Benzene or thiophene derivative and use thereof as VAP-1 inhibitor

Also Published As

Publication number Publication date
JP2013163701A (ja) 2013-08-22
EP2172221A1 (en) 2010-04-07
CN101784285B (zh) 2012-12-05
JPWO2009001857A1 (ja) 2010-08-26
EP2172221A4 (en) 2010-06-23
EP2599498A1 (en) 2013-06-05
CN101784285A (zh) 2010-07-21
CA2691520A1 (en) 2008-12-31
KR20100034024A (ko) 2010-03-31
US20100190834A1 (en) 2010-07-29
CN102920698A (zh) 2013-02-13
TW200913999A (en) 2009-04-01

Similar Documents

Publication Publication Date Title
WO2008070268A3 (en) Pharmaceutical compositions
WO2010056022A3 (en) Melanocortin receptor agonists
WO2009057079A3 (en) Novel pyrimidine derivatives
WO2007052289A3 (en) Novel dispersible tablet composition
WO2010128050A3 (en) Dihydroorotate - dehydrogenasee inhibitors as virostatic compounds
WO2007086001A3 (en) Novel pyridine derivatives
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
WO2008006528A3 (en) Pharmaceutical compositions comprising levetiracetam
WO2007093627A3 (de) Biozide zusammensetzung
WO2006065479A3 (en) Substituted phenols as active agents inhibiting vegf production
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2007127292A3 (en) Tigeycline crystalline forms and processes for preparation thereof
WO2009144550A3 (en) Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality
WO2009111633A3 (en) Mercaptan and seleno-mercaptan compounds and methods of using them
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2011005052A8 (en) Novel arylpiperazine-containing imidazole 4-carboxamide derivatives and pharmaceutical composition comprising same
EP2316420A8 (en) Method to reduce pain
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2006096518A3 (en) Improved gacyclidine formulations
WO2008033757A3 (en) 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
WO2010005148A3 (en) Novel isoindolinone derivatives having inhibitory activity against t-type calcium channel and method for preparation thereof
WO2009133455A3 (en) Pharmaceutical composition of clodipogrel
WO2009103813A3 (de) Fungizide zusammensetzungen mit 3'-brom-2,3,4,6'-tetramethoxy-2'-6-dimethylbenzophenon
WO2008084710A1 (ja) ヘルペスウィルス感染阻害剤、ヘルペスウィルスの感染阻害方法およびその利用

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880104348.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790612

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009520615

Country of ref document: JP

Ref document number: 2691520

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008790612

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107001537

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12665914

Country of ref document: US